We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences Sapien 3 System Recall Classified Class I
Read MoreHide Full Article
FDA has classified its recent recall of Edwards Lifesciences’ (EW - Free Report) Sapien 3 Ultra delivery system as Class I due to health risks associated with its use. However, the products will remain in the market as of now.
The recall comes a week after the company's Sapien 3 and Sapien 3 Ultra heart valves’ receipt of FDA approval for use in surgeries at low death risk. Following the news of this major setback, shares of Edwards Lifesciences have dropped 2.6% to close at $216.67 yesterday.
More About The Product Recall
The Sapien 3 Ultra delivery system has been designed to deliver and deploy a transcatheter heart valve to replace a diseased aortic valve without open-heart surgery.
In July 2019, Edwards Lifesciences initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the system. The company issued a safety notice to customers and physicians. It recommended that the balloon in the delivery system be inflated at a slow and consistent pace while deploying the heart valve to avoid rupture.
The use of affected product may cause serious adverse health consequences as well as death. Patients who had a transcatheter aortic valve replacement procedure using the Edwards SAPIEN 3 Ultra Transcatheter Heart System are most susceptible to these risks.
As per a Reuters article, the company stated it is not removing the delivery system from the market and has updated the instructions for use to its customers. However, the FDA has used the term "recall" since it is a case of a manufacturer undertaking a remedial action. The regulatory body stated that the balloons that ruptured during implantation procedures made it difficult for the recovery of the valve into the catheter and withdrawal of the the system from a patient's body. The FDA also stated that the recall includes 1,585 heart valve delivery systems.
According to the company, the FDA's decision to categorize the issue as a Class I recall should be acknowledged of its seriousness.
However, Edwards Lifesciences has added that the recall is not likely to affect the company's revenue projection.
Recent Product Recalls
In July 2019, FDA stated that three deaths had been reported thanks to Edwards Lifesciences’ recall of one of its heart devices. The regulatory body stated the company’s voluntary recall of its IntraClude intra-aortic occlusion device in May has now been categorized as Class I.FDA also noted that the recall affects more than 750 devices in the United States. The recall was made on account of risk of balloon rupture during use of the devices. The company had received as many as 22 complaints related to the device.
Price Performance
In the past year, the company’s shares have outperformed the industry. The stock has gained 52.9% compared with the industry’s 4.6% fall.
Zacks Rank and Key Picks
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold).
Medtronic’s long-term earnings growth rate is expected at 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Amedisys’ long-term earnings growth rate is expected to be 16.3%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Edwards Lifesciences Sapien 3 System Recall Classified Class I
FDA has classified its recent recall of Edwards Lifesciences’ (EW - Free Report) Sapien 3 Ultra delivery system as Class I due to health risks associated with its use. However, the products will remain in the market as of now.
The recall comes a week after the company's Sapien 3 and Sapien 3 Ultra heart valves’ receipt of FDA approval for use in surgeries at low death risk. Following the news of this major setback, shares of Edwards Lifesciences have dropped 2.6% to close at $216.67 yesterday.
More About The Product Recall
The Sapien 3 Ultra delivery system has been designed to deliver and deploy a transcatheter heart valve to replace a diseased aortic valve without open-heart surgery.
In July 2019, Edwards Lifesciences initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the system. The company issued a safety notice to customers and physicians. It recommended that the balloon in the delivery system be inflated at a slow and consistent pace while deploying the heart valve to avoid rupture.
The use of affected product may cause serious adverse health consequences as well as death. Patients who had a transcatheter aortic valve replacement procedure using the Edwards SAPIEN 3 Ultra Transcatheter Heart System are most susceptible to these risks.
As per a Reuters article, the company stated it is not removing the delivery system from the market and has updated the instructions for use to its customers. However, the FDA has used the term "recall" since it is a case of a manufacturer undertaking a remedial action. The regulatory body stated that the balloons that ruptured during implantation procedures made it difficult for the recovery of the valve into the catheter and withdrawal of the the system from a patient's body. The FDA also stated that the recall includes 1,585 heart valve delivery systems.
According to the company, the FDA's decision to categorize the issue as a Class I recall should be acknowledged of its seriousness.
However, Edwards Lifesciences has added that the recall is not likely to affect the company's revenue projection.
Recent Product Recalls
In July 2019, FDA stated that three deaths had been reported thanks to Edwards Lifesciences’ recall of one of its heart devices. The regulatory body stated the company’s voluntary recall of its IntraClude intra-aortic occlusion device in May has now been categorized as Class I.FDA also noted that the recall affects more than 750 devices in the United States. The recall was made on account of risk of balloon rupture during use of the devices. The company had received as many as 22 complaints related to the device.
Price Performance
In the past year, the company’s shares have outperformed the industry. The stock has gained 52.9% compared with the industry’s 4.6% fall.
Zacks Rank and Key Picks
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Medtronic (MDT - Free Report) , Baxter (BAX - Free Report) and Amedisys (AMED - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is expected at 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Amedisys’ long-term earnings growth rate is expected to be 16.3%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>